Clinical trials: Progressive Glioblastoma
Recurrent Glioblastoma Planned for Reoperation
Patupilone (EPO 906) in Patients With Recurrent or Progressive Glioblastoma
Patupilone trial for patients with recurrent glioblastoma, which are planned for re-operation. Objectives: prolongation of PFS compared to patients with re-operation only, Patupilone tumor concentrations, pharmacokinetic…
- Trial name
- NCT00715013
- Testing
- Patupilone
- Volunteers
- 9 people
- Sponsor
- University of Zurich
Glioblastoma, Recurrent Glioblastoma
VB-111 in Surgically Accessible Recurrent/Progressive GBM
This research study is studying a new viral cancer therapy, ofranergene obadenovec (VB-111), for recurrent or progressive glioblastoma (GBM), a brain tumor that is growing or progressing despite earlier treatment.
- Trial name
- NCT04406272
- Testing
- VB11, Surgery, Bevacizumab
- Where
- 4 sites in United States
- Volunteers
- 15 people
- Sponsor
- Dana-Farber Cancer Institute
Glioblastoma, Glioma
A Study of GDC-0084 in Patients With Progressive or Recurrent High-Grade Glioma
This open-label, multicenter, Phase I, dose-escalating study will evaluate the safety and tolerability, pharmacokinetics, pharmacodynamics and efficacy of GDC-0084 in patients with progressive or recurrent high-grade glioma.
- Trial name
- NCT01547546
- Testing
- GDC-0084
- Where
- 5 sites in United States, Spain
- Volunteers
- 29 people
- Sponsor
- Genentech, Inc.
Brain and Central Nervous System Tumors
Gefitinib in Treating Patients With Recurrent or Progressive CNS Tumors
RATIONALE: Biological therapies such as gefitinib may interfere with the growth of tumor cells and slow the growth of CNS tumors.
- Trial name
- NCT00025675
- Testing
- gefitinib
- Where
- 12 sites in United States
- Volunteers
- 105 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Glioma, Medulloblastoma
PLX038 in Primary Central Nervous System Tumors Containing MYC or MYCN Amplifications
Background: About 90,000 new cases of brain and spinal cord tumors are diagnosed annually in the United States. Most of these tumors are benign; however, about 30% are malignant, and 35% of people with malignant tumors in the…
- Conditions
- Glioma, Medulloblastoma, Ependymoma, Glioblastoma
- Trial name
- NCT06161519
- Testing
- PLX038
- Where
- United States
- Volunteers
- 146 people
- Sponsor
- National Cancer Institute (NCI)
Glioblastoma IDH (Isocitrate Dehydrogenase) Wildtype, Astrocytoma, Grade III
A Study of Zedoresertib (Debio 0123) in Combination With Temozolomide in Adult Participants With Recurrent or Progressive Glioblastoma and of Zedoresertib (Debio 0123) in Combination With Temozolomide and Radiotherapy in Adult Participants With Newly Diagnosed Glioblastoma
The primary purpose of the Phase 1 (Dose Escalation) of this study is to identify the dose-limiting toxicities (DLTs) of zedoresertib combined with temozolomide (TMZ) (Arm A) and with TMZ and radiotherapy (RT) (Arms B and C) and…
- Trial name
- NCT05765812
- Testing
- Zedoresertib, Temozolomide, Radiotherapy
- Where
- 16 sites in United States, Spain and 1 more
- Volunteers
- 116 people
- Sponsor
- Debiopharm International SA
Brain Tumor, Glioblastoma
Vaccination With Dendritic Cells Loaded With Brain Tumor Stem Cells for Progressive Malignant Brain Tumor
This is a single center Phase I study to determine the safety and maximum tolerated dose (MTD) of autologous dendritic cells (DCs) loaded with allogeneic brain tumor stem cells administered as a vaccination in children and adults…
- Conditions
- Brain Tumor, Glioblastoma, Medulloblastoma, Ependymoma
- Trial name
- NCT01171469
- Testing
- Dendritic Cells, Imiquimod
- Where
- United States
- Volunteers
- 8 people
- Sponsor
- Masonic Cancer Center, University of Minnesota
Glioblastoma Multiforme
Study to Evaluate the Efficacy, Safety, Pharmacokinetics and Pharmacodynamic Effects of PQR309 in Glioblastoma Patients
PQR309 is an oral, dual pan-PI3K (phosphatidylinositol 3-kinase phosphoinositide 3-kinase) and mTOR (mammilian target of rapamycin) inhibitor that penetrates the blood-brain barrier at pharmacodynamically active concentrations.
- Trial name
- NCT02850744
- Testing
- PQR309
- Where
- Switzerland
- Volunteers
- 10 people
- Sponsor
- PIQUR Therapeutics AG
Metastatic Malignant Neoplasm in the Brain, Metastatic Melanoma
STAT3 Inhibitor WP1066 in Treating Patients With Recurrent Malignant Glioma or Progressive Metastatic Melanoma in the Brain
This phase I trial studies the side effects and best dose of STAT3 inhibitor WP1066 in treating patients with malignant glioma that has come back or melanoma that has spread to the brain and is growing, spreading, or getting…
- Conditions
- Metastatic Malignant Neoplasm in the Brain, Metastatic Melanoma, Recurrent Brain Neoplasm, Recurrent Glioblastoma
- Trial name
- NCT01904123
- Testing
- Laboratory Biomarker Analysis, Pharmacological Study, STAT3 Inhibitor WP1066
- Where
- United States
- Volunteers
- 8 people
- Sponsor
- M.D. Anderson Cancer Center
Brain and Central Nervous System Tumors
Iodine I 131 Monoclonal Antibody TNT-1/B in Treating Patients With Progressive or Recurrent Glioblastoma Multiforme
RATIONALE: Radiolabeled monoclonal antibodies, such as iodine I 131 monoclonal antibody TNT-1/B (^131I MOAB TNT-1/B), can find tumor cells and carry tumor-killing substances to them without harming normal cells.
- Trial name
- NCT00128635
- Testing
- iodine I 131 monoclonal antibody TNT-1/B
- Where
- 4 sites in United States
- Volunteers
- 22 people
- Sponsor
- Abramson Cancer Center at Penn Medicine
Glioblastoma Multiforme, Anaplastic Astrocytoma
Dose Escalation Study to Determine the Safety of IFN-Beta Gene Transfer in the Treatment of Grade III & Grade IV Gliomas
In this study an investigational replication-defective, recombinant adenovirus expressing the interferon-beta gene (BG00001) will be directly injected into tumors, in patients with recurrent Grade III and Grade IV Gliomas, in…
- Conditions
- Glioblastoma Multiforme, Anaplastic Astrocytoma, Oligoastrocytoma, Mixed, Gliosarcoma
- Trial name
- NCT00031083
- Testing
- Interferon-beta
- Where
- 5 sites in United States
- Volunteers
- 12 people
- Sponsor
- Biogen
Brain and Central Nervous System Tumors
Temozolomide and O6-benzylguanine in Treating Patients With Newly Diagnosed, Recurrent, or Progressive Anaplastic Glioma
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells.
- Trial name
- NCT00006474
- Testing
- O6-benzylguanine, temozolomide, conventional surgery
- Where
- United States
- Sponsor
- Duke University
Glioblastoma
Imaging Biomarkers of Tissue Microstructure and Vasculature as Predictors of Glioblastoma Multiforme
This study is for subjects with a diagnosis of a brain tumor called glioblastoma that is being treated with bevacizumab. This study will use a new MRI technique to compare the images of blood vessels and tumor structure to the…
- Trial name
- NCT01604590
- Testing
- Magnetic Resonance Imaging (MRI)
- Where
- United States
- Volunteers
- 13 people
- Sponsor
- Medical University of South Carolina
Glioblastoma
A Dose Escalation Phase I Study Of Human- Recombinant Bone Morphogenetic Protein 4 Administrated Via CED In GBM Patients
The purpose of the study is to evaluate the feasibility and safety of intra-tumor and interstitial therapy with hBMP4 in increasing doses in patients with progressive and/or multiple recurrent Glioblastoma multiforme (GBM).
- Trial name
- NCT02869243
- Testing
- hrBMP4
- Where
- 4 sites in Israel, Italy and 1 more
- Volunteers
- 15 people
- Sponsor
- Stemgen
Glioblastoma Multiforme
Dose-Escalation Study of Carboplatin Administration Into the Brain for Glioblastoma Multiforme
High-grade gliomas are the commonest primary malignant brain tumours in adults, affecting approximately 5000 people per year in the UK.
- Trial name
- NCT01317212
- Testing
- Peritumoural carboplatin administration.
- Where
- United Kingdom
- Sponsor
- North Bristol NHS Trust
Glioblastoma Multiforme
Efficacy, Safety and CNS Exposure of G-202 (Mipsagargin) in Patients With Recurrent or Progressive Glioblastoma
This study will evaluate if a drug called G-202 can be safely used to treat people with glioblastoma (GBM) that has progressed or recurred. G-202 is given by intravenous infusion on three consecutive days of a 28-day cycle.
- Trial name
- NCT02067156
- Testing
- G-202
- Where
- United States
- Volunteers
- 26 people
- Sponsor
- GenSpera, Inc.
Adult Glioblastoma
Molecular Profiling in Guiding Individualized Treatment Plan in Adults With Recurrent/Progressive Glioblastoma
This current study will use a new treatment approach based on each patient's tumor genomic profiling consisting of whole genome sequencing, exome analysis, and RNA sequencing as well as predictive modeling.
- Trial name
- TGEN (NCT02060890)
- Testing
- specialized tumor board recommendation
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- University of California, San Francisco
Glioblastoma, Gliosarcoma
Radiosurgery Plus Bevacizumab in Glioblastoma
RATIONALE: Radiosurgery can send x-rays directly to the tumor and cause less damage to normal tissue. Monoclonal antibodies, such as bevacizumab, can block tumor growth in different ways.
- Conditions
- Glioblastoma, Gliosarcoma, Brain Tumor
- Trial name
- NCT01086345
- Testing
- radiosurgery, bevacizumab, irinotecan hydrochloride
- Where
- United States
- Volunteers
- 9 people
- Sponsor
- Case Comprehensive Cancer Center
Brain and Central Nervous System Tumors, Unspecified Childhood Solid Tumor, Protocol Specific
Valproic Acid in Treating Young Patients With Recurrent or Refractory Solid Tumors or CNS Tumors
RATIONALE: Drugs used in chemotherapy, such as valproic acid, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT00107458
- Testing
- valproic acid
- Where
- 17 sites in United States, Canada
- Volunteers
- 26 people
- Sponsor
- Children's Oncology Group
Malignant Gliomas
Cetuximab, Bevacizumab and Irinotecan for Patients With Malignant Glioblastomas
Irinotecan has demonstrated activity in malignant gliomas in multiple phase II studies. The activity is limited, with an approximately 15 % response rate and a progression-free survival of 3-5 months.
- Trial name
- NCT00463073
- Testing
- Cetuximab, Bevacizumab, Irinotecan
- Where
- 3 sites in Denmark
- Volunteers
- 32 people
- Sponsor
- Copenhagen University Hospital, Rigshospitalet